Combined therapeutic strategies hold promises in augmenting antigen release to enhance
anti-tumor immunity, which have garnered attention in numerous scholarly reviews. Beyond …

Immunogenic cell death (ICD) is a unique mode of cell death, which can release
immunogenic damage‐associated molecular patterns (DAMPs) and tumor‐associated …

Nanocarrier-based cytoplasmic protein delivery offers opportunities to develop protein
therapeutics; however, many delivery systems are positively charged, causing severe toxic …

Developing a multifunctional nanoplatform to achieve efficient theranostics of tumors
through multi‐pronged strategies remains to be challenging. Here, the design of the …

Surgical excision is the first choice for clinical cancer therapy. However, major challenges,
such as postoperative tumor recurrence and unsatisfactory wound healing after surgery …

Innate immunity triggered by the cGAS/STING pathway has the potential to improve cancer
immunotherapy. Previously, the authors reported that double‐stranded DNA (dsDNA) …

The heterogeneity of tumor microenvironment (TME) and existence of cancer stem cells
(CSCs) severely impede the therapeutic efficacy of current anti-tumor treatments, which is …

The development of drug delivery strategies with the desired immunomodulation effects to
alleviate tumor drug resistance remains a challenge. Herein, low-generation poly …

Introduction Triple-negative breast cancer (TNBC) is a highly aggressive subtype with a poor
prognosis. Current single-agent checkpoint therapy has limited effectiveness in TNBC …

Herein, we constructed a paclitaxel (PTX) prodrug (PA) by conjugating PTX with acrylic acid
as a cysteine-depleting agent. The as-synthesized PA can assemble with …